Skip to Content

Making Bacteria into Drug Blimps

A new approach can make bacteria deliver medicine where it’s needed.

Coaxing bacteria into producing medicines for humans’ benefit has been a common quest. But the goal of getting those bacteria to drop loads of medicine at a specific target inside the body is more unusual.

According to research presented Tuesday at the American Chemical Society meeting in Anaheim, California, that goal is now within sight. The researchers, led by William Bentley of the University of Maryland, say their engineered bacteria could serve as on-the-go nanofactories inside the body, both to produce illness-fighting agents and to deliver them to the correct spots.

They developed a prototype using a strain of the E. coli bacterium specially engineered with a targeting molecule attached to its outer surface. The bacterium cruises around, finds its target, attaches to it, and begins producing preprogrammed drugs. In the laboratory, in vitro, the prototype was able both to find targeted intestinal cells and to produce chemical signals that triggered nearby bacteria to produce proteins they typically don’t make.

“We envision a cell that seeks out a cancer tumor and locks on to it, then starts to create its own antitumor drug and deliver it on the spot,” said Bentley. He said this method could also treat conditions such as other gastrointestinal illnesses or vitamin deficiency. “One thing that is different from other treatments is that this is site-specific,” he said. “Most medicines kill all the cells or tissue, while this system only delivers drugs to one spot.”

The bacterial drug factories could also produce signaling molecules to communicate with natural bacteria and keep them from starting an infection. They could, Bentley said, be injected or swallowed as probiotics—beneficial live organisms—though clinical applications of the technology are years away. 

Other researchers say that transferring the process from the lab to a person can be difficult. “Getting a lab strain of E. coli to survive the stomach is going to be tricky,” says J. Christopher Anderson, a bioengineering professor at the University of California, Berkeley. “There are issues to the genetic stability of the organisms, and depending on the specific goal, the ability to get enough bacteria into the intestines to do something could be tricky.” Anderson says that the intestine is a good place to start for engineered bacteria therapy because E. coli last longer in the intestines than in other parts of the body.

Getting bacterial dirigibles past regulatory hurdles could also be problematic, Anderson says. “Treating chronic diseases with gastrointestinal engineered bacteria will necessarily result in environmental release. Since these bacteria produce biologically active chemicals or proteins to be functional, there are likely to be significant safety concerns and thereby barriers to getting them approved.”

Keep Reading

Most Popular

Rendering of Waterfront Toronto project
Rendering of Waterfront Toronto project

Toronto wants to kill the smart city forever

The city wants to get right what Sidewalk Labs got so wrong.

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun
Yann LeCun

Yann LeCun has a bold new vision for the future of AI

One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.

images created by Google Imagen
images created by Google Imagen

The dark secret behind those cute AI-generated animal images

Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.